Hybio Pharmaceutical Co., Ltd.

300199

CNE1000011T7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-19 EDT			5-day change	1st Jan Change
11.77 ^CNY	-0.08%		+7.98%	-13.33%

05-29	3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	MT
05-29	Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical	MT

Hybio Pharmaceutical Co., Ltd. Announces Directors Appointments

January 17, 2020 at 02:32 pm

Hybio Pharmaceutical Co., Ltd. at its EGM held on January 16, 2020 approved appointment of Zeng Shaobin and PINXIANG YU as directors.

Latest news about Hybio Pharmaceutical Co., Ltd.

3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	05-29	MT
Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical	05-29	MT
Hybio Pharmaceutical Gets Nod to Market Ganirelix Acetate Injection	05-28	MT
Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	05-21	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	04-25	MT
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5%	04-18	MT
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	12-06	MT
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6%	11-06	MT
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	23-09-21	MT
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client	23-09-21	MT
Hybio Pharmaceutical Co., Ltd.(XSEC:300199) added to S&P Global BMI Index	23-09-18	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 254.12 million in funding	23-08-10	CI
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient	23-07-12	MT
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery	23-07-11	MT
Hybio Pharmaceutical Gets Nod to Trial Linaclotide Capsules	23-05-17	MT
Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.	23-04-26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Li Xiulan completed the acquisition of 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin.	23-03-27	CI
Hybio Pharma’s COVID-19 Nasal Spray Wins FDA Nod For Clinical Trial	23-02-28	MT
Li Xiulan agreed to acquire a 5% stake in Hybio Pharmaceutical Co., Ltd. (SZSE : 300199) from Zeng Shaogui, Zeng Shaoqiang and Zeng Shaobin for approximately CNY 450 million.	23-02-13	CI

Chart Hybio Pharmaceutical Co., Ltd.

Duration

Period

More charts

Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Companyâs products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company's newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HYBIO PHARMACEUTICAL CO., LTD.	-13.33%	1.43B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.80%	43.26B
OTSUKA HOLDINGS CO., LTD.	+17.47%	21.6B
SANDOZ GROUP AG	+21.73%	15.93B
CIPLA LIMITED	+23.95%	15.1B
ZYDUS LIFESCIENCES LIMITED	+57.96%	12.95B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-16.22%	6.29B
ASPEN PHARMACARE HOLDINGS LIMITED	+19.77%	6.04B
STADA ARZNEIMITTEL	-8.87%	5.73B